Extracellular vesicles and miRNA-based therapies in triple-negative breast cancer: advances and clinical perspectives

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive and challenging subtypes for treatment, due to the lack of hormone receptors and the human epidermal growth factor receptor 2 (HER2) protein. The identification of new molecular targets is important for the development of targeted and specific therapies for TNBC patients. MicroRNAs (miRNAs) have emerged as promising molecular targets, being involved in cellular processes such as cell survival, apoptosis, differentiation, carcinogenesis, and metastasis. Extracellular vesicles (EVs) have gained prominence in areas such as drug delivery, immune modulation, biomarkers for diagnosis and prognosis, and therapeutics, due to their use as vehicles for the delivery of miRNAs, regulation of gene expression, and development of combined therapeutic strategies. In particular, mesenchymal stem cell-derived EVs (MSC-derived EVs) can transfer proteins, mRNAs/miRNAs, or DNA molecules and are being considered safer treatment options due to their inability to directly form tumors and contain lower amounts of membrane proteins such as MHC molecules. Numerous studies have highlighted the role of miRNAs in EVs in TNBC tumorigenesis, with a focus on diagnosis, prognosis, treatment selection, and monitoring. However, the development of therapies with EVs, especially MSC-derived EVs, is still in its infancy. Therefore, the aim of this review is to address new therapeutic strategies based on the delivery of miRNAs through EVs, with a focus on MSC-derived EVs, for the treatment of TNBC as an innovative therapy in oncology.

Keywords

Extracellular vesicles (EVs) / miRNAs / EVs-miRNAs therapies / mesenchymal stem cells (MSCs) / triple-negative breast cancer (TNBC)

References

[1] Siegel RL,Jemal A.Cancer statistics, 2024.CA Cancer J Clin2024;74:12-49

[2] Łukasiewicz S,Forma A,Sitarz R.Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review.Cancers2021;13:4287 PMCID:PMC8428369

[3] Yin L,Bian XW.Triple-negative breast cancer molecular subtyping and treatment progress.Breast Cancer Res2020;22:61 PMCID:PMC7285581

[4] Abdul-Rahman T,Herrera-Calderón RE.Extracellular vesicle-mediated drug delivery in breast cancer theranostics.Discov Oncol2024;15:181 PMCID:PMC11116322

[5] Leone JP,Leone J.Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool.Eur J Cancer2023;189:112930

[6] Sonkin D,Teicher BA.Cancer treatments: past, present, and future.Cancer Genet2024;286-7:18-24 PMCID:PMC11338712

[7] Sabit H,Tombuloglu H,Tombuloglu G.Triple negative breast cancer in the era of miRNA.Crit Rev Oncol Hematol2021;157:103196

[8] Xunian Z.Biology and therapeutic potential of mesenchymal stem cell-derived exosomes.Cancer Sci2020;111:3100-10 PMCID:PMC7469857

[9] Wang N,Song H.Mesenchymal stem cell-derived extracellular vesicles for regenerative applications and radiotherapy.Cell Transplant2025;34:9636897241311019 PMCID:PMC11713979

[10] Meng Y,Ke X.Extracellular vesicles-based vaccines: emerging immunotherapies against cancer.J Control Release2024;378:438-59

[11] Fusco C,Spatocco I.Extracellular vesicles as human therapeutics: a scoping review of the literature.J Extracell Vesicles2024;13:e12433 PMCID:PMC11089593

[12] Martellucci S,Angelucci A,Caraglia M.Extracellular vesicles: new endogenous shuttles for miRNAs in cancer diagnosis and therapy?.Int J Mol Sci2020;21:6486 PMCID:PMC7555972

[13] Cantini L,Cava C.Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer.Nucleic Acids Res2019;47:2205-15 PMCID:PMC6412120

[14] Ho PT,Le LT.MicroRNA-based diagnosis and therapy.Int J Mol Sci2022;23:7167 PMCID:PMC9266664

[15] Sepúlveda F,Guzmán K,Lobos-González L.EV-miRNA-mediated intercellular communication in the breast tumor microenvironment.Int J Mol Sci2023;24:13085 PMCID:PMC10487525

[16] Shahbandi A,Jackson JG.TP53 mutations and outcomes in breast cancer: reading beyond the headlines.Trends Cancer2020;6:98-110 PMCID:PMC7931175

[17] Shiovitz S.Genetics of breast cancer: a topic in evolution.Ann Oncol2015;26:1291-9 PMCID:PMC4478970

[18] Wernli KJ,Trentham-Dietz A.Antidepressant medication use and breast cancer risk.Pharmacoepidemiol Drug Saf2009;18:284-90 PMCID:PMC2720762

[19] Perou CM,Eisen MB.Molecular portraits of human breast tumours.Nature2000;406:747-52

[20] Tsang JYS.Molecular classification of breast cancer.Adv Anat Pathol2020;27:27-35

[21] Goldhirsch A, Winer EP, Coates AS, et al; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206-23. PMCID:PMC3755334

[22] Roy M,Ulaner GA.Molecular classification of breast cancer.PET Clin2023;18:441-58

[23] Badve S,Schnitt SJ.Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.Mod Pathol2011;24:157-67

[24] Won KA.Triple-negative breast cancer therapy: current and future perspectives (Review).Int J Oncol2020;57:1245-61 PMCID:PMC7646583

[25] Santonja A,Lluch A.Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.Oncotarget2018;9:26406-16 PMCID:PMC5995183

[26] Lehmann BD,Chen X.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest2011;121:2750-67 PMCID:PMC3127435

[27] Liang Y,Song X.Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets.Semin Cancer Biol2020;60:14-27

[28] Hashemi M,Orouei S.EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions.Biomed Pharmacother2022;155:113774

[29] Park M,Ko S,Mo K.Breast cancer metastasis: mechanisms and therapeutic implications.Int J Mol Sci2022;23:6806 PMCID:PMC9224686

[30] Corso G,De Angelis SP.E-cadherin deregulation in breast cancer.J Cell Mol Med2020;24:5930-6 PMCID:PMC7294130

[31] Mendonsa AM,Gumbiner BM.E-cadherin in contact inhibition and cancer.Oncogene2018;37:4769-80 PMCID:PMC6119098

[32] Caramel J,Puisieux A.Pleiotropic roles for ZEB1 in cancer.Cancer Res2018;78:30-5

[33] Cheng L,Gu YJ,Wang Y.ZEB1: new advances in fibrosis and cancer.Mol Cell Biochem2021;476:1643-50

[34] Siersbæk R,Nagarajan S.IL6/STAT3 signaling hijacks ER enhancers to drive breast cancer metastasis.Cancer Cell2020;38:412-23.e9 PMCID:PMC7116707

[35] Lehmann BD,Chen X.Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection.PLoS One2016;11:e0157368 PMCID:PMC4911051

[36] Yao H,Yan S.Triple-negative breast cancer: is there a treatment on the horizon?.Oncotarget2017;8:1913-24 PMCID:PMC5352107

[37] Calin GA,Dumitru CD.Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.Proc Natl Acad Sci U S A2004;101:2999-3004 PMCID:PMC365734

[38] Xu J,Jia QJ.Roles of miRNA and lncRNA in triple-negative breast cancer.J Zhejiang Univ Sci B2020;21:673-89 PMCID:PMC7519626

[39] Berti FCB,Nunes-Souza E.Extracellular vesicles-associated miRNAs in triple-negative breast cancer: from tumor biology to clinical relevance.Life Sci2024;336:122332

[40] Ding G,Shang J,Ning H.LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism.Onco Targets Ther2017;10:3241-7 PMCID:PMC5501625

[41] Yang C,Ruan X.The dual regulatory role of MiR-181a in breast cancer.Cell Physiol Biochem2017;44:843-56

[42] Taylor MA,Thompson CL,Schiemann WP.TGF-β upregulates miR-181a expression to promote breast cancer metastasis.J Clin Invest2013;123:150-63 PMCID:PMC3533297

[43] Liu Y,Bao PP.Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.Breast Cancer Res Treat2015;152:183-91 PMCID:PMC4484742

[44] Tsouko E,Frigo DE,Williams C.miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene.Carcinogenesis2015;36:1051-60 PMCID:PMC5975720

[45] Sossey-Alaoui K,Szpak D,Plow EF.The Kindlin-2 regulation of epithelial-to-mesenchymal transition in breast cancer metastasis is mediated through miR-200b.Sci Rep2018;8:7360 PMCID:PMC5943603

[46] Zheng Q,Zhang D.miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and α1,3-fucosylated glycans.Oncogenesis2017;6:e358 PMCID:PMC5541710

[47] Ren Y,Yu K.microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells.Mol Med Rep2014;10:315-21

[48] Fang LL,Huang LR.Potent inhibition of miR-34b on migration and invasion in metastatic prostate cancer cells by regulating the TGF-β pathway.Int J Mol Sci2017;18:2762 PMCID:PMC5751361

[49] Zeng Z,Zhu D,Yang M.Low expression of circulating microRNA-34c is associated with poor prognosis in triple-negative breast cancer.YMJ2017;58:697-702 PMCID:PMC5447098

[50] Imani S,Cheng J.MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion.Oncotarget2017;8:21362-79 PMCID:PMC5400590

[51] Terkelsen T,Gromov P.Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.Breast Cancer Res2020;22:73 PMCID:PMC7329449

[52] Piasecka D,Kordek R,Romanska H.MicroRNAs in regulation of triple-negative breast cancer progression.J Cancer Res Clin Oncol2018;144:1401-11 PMCID:PMC6061037

[53] Cecchin R,Witwer K.Extracellular vesicles: the next generation in gene therapy delivery.Mol Ther2023;31:1225-30 PMCID:PMC10188631

[54] Dasgupta I.Recent advances in miRNA delivery systems.Methods Protoc2021;4:10 PMCID:PMC7839010

[55] Heusermann W,Trojer D.Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER.J Cell Biol2016;213:173-84 PMCID:PMC5084269

[56] Younis MA,Abdellatif AAH,Harashima H.Clinical translation of nanomedicines: challenges, opportunities, and keys.Adv Drug Deliv Rev2022;181:114083

[57] Baruah H,Basak D.Exosome: from biology to drug delivery.Drug Deliv Transl Res2024;14:1480-516

[58] Wolf P.The nature and significance of platelet products in human plasma.Br J Haematol1967;13:269-88

[59] Raposo G,Stoorvogel W.B lymphocytes secrete antigen-presenting vesicles.J Exp Med1996;183:1161-72 PMCID:PMC2192324

[60] Théry C,Aikawa E.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV 2014 guidelines.J Extracell Vesicles2018;7:1535750 PMCID:PMC6322352

[61] Valadi H,Bossios A,Lee JJ.Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.Nat Cell Biol2007;9:654-9

[62] Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[63] Brown L,Prados-Rosales R.Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi.Nat Rev Microbiol2015;13:620-30 PMCID:PMC4860279

[64] Syromiatnikova V,Gomzikova M.Methods of the large-scale production of extracellular vesicles.Int J Mol Sci2022;23:10522 PMCID:PMC9506336

[65] de Toledo Martins S, Szware P, Goldenberg S, Alves L. Extracellular vesicles in Fungi: composition and functions. Curr Top Microbiol Immunol 2019;422:45-59.

[66] Zhang X,Takeda A,Nagai Y.Comparison of serum and plasma as a source of blood extracellular vesicles: increased levels of platelet-derived particles in serum extracellular vesicle fractions alter content profiles from plasma extracellular vesicle fractions.PLoS One2022;17:e0270634 PMCID:PMC9231772

[67] Friedenstein AJ,Lalykina KS.The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells.Cell Tissue Kinet1970;3:393-403

[68] Yang G,Liu Y.Immunomodulatory mechanisms and therapeutic potential of mesenchymal stem cells.Stem Cell Rev Rep2023;19:1214-31 PMCID:PMC10103048

[69] Zvaifler NJ,Adams G.Mesenchymal precursor cells in the blood of normal individuals.Arthritis Res2000;2:477-88 PMCID:PMC17820

[70] Majore I,Stahl F,Kasper C.Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord.Stem Cell Rev Rep2011;7:17-31

[71] Miana VV.Adipose tissue stem cells in regenerative medicine.Ecancermedicalscience2018;12:822 PMCID:PMC5880231

[72] Hong P,Wu Y,Tang Z.The functions and clinical application potential of exosomes derived from adipose mesenchymal stem cells: a comprehensive review.Stem Cell Res Ther2019;10:242 PMCID:PMC6686455

[73] Keshtkar S,Ghahremani MH.Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine.Stem Cell Res Ther2018;9:63 PMCID:PMC5845209

[74] Johnson V,Kumar US.Surface-engineered extracellular vesicles in cancer immunotherapy.Cancers2023;15:2838 PMCID:PMC10216164

[75] Lener T,Aigner L.Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.J Extracell Vesicles2015;4:30087 PMCID:PMC4698466

[76] Guo Y,Wu L,Wu P.Mesenchymal stem cell-derived extracellular vesicles: pleiotropic impacts on breast cancer occurrence, development, and therapy.Int J Mol Sci2022;23:2927 PMCID:PMC8954385

[77] Roszkowski S.Therapeutic potential of mesenchymal stem cell-derived exosomes for regenerative medicine applications.Clin Exp Med2024;24:46 PMCID:PMC10907468

[78] Liu X,Li X.Application of mesenchymal stem cells exosomes as nanovesicles delivery system in the treatment of breast cancer.Int J Pharm2024;666:124732

[79] Mir P, Hussain MS, Ahmad Khanday M, Mohi-Ud-Din R, Pottoo FH, Hasssan Mir R. Immunomodulatory roles of mesenchymal stem cell-derived extracellular vesicles: a promising therapeutic approach for autoimmune diseases.Curr Stem Cell Res Ther2024;Epub ahead of print:

[80] Lai P,Guo L,Du X.Novel insights into MSC-EVs therapy for immune diseases.Biomark Res2019;7:6 PMCID:PMC6423844

[81] Zhou X,Chen Y.Mesenchymal stem cell-derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway.Int J Oncol2019;54:1843-52

[82] O'Brien KP,Gilligan KE.Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.Oncogene2018;37:2137-49

[83] Biswas S,Roy Chowdhury S.Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer.J Immunol2019;203:3447-60 PMCID:PMC6994919

[84] Pakravan K,Sadeghizadeh M.MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells.Cell Oncol2017;40:457-70

[85] Gong C,Wang Z.Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy.J Nanobiotechnology2019;17:93 PMCID:PMC6721253

[86] Farouk AH,Fathy BA.Stem cells derived exosomes as biological nano carriers for VCR sulfate for treating breast cancer stem cells.Sci Rep2024;14:10964 PMCID:PMC11094037

[87] Jahangiri B,Asadollahi E,Sadeghizadeh M.Dual impacts of mesenchymal stem cell-derived exosomes on cancer cells: unravelling complex interactions.J Cell Commun Signal2023;17:1229-47 PMCID:PMC10713965

[88] Shen D.Mesenchymal stem cell-derived exosomes regulate the polarization and inflammatory response of macrophages via miR-21-5p to promote repair after myocardial reperfusion injury.Ann Transl Med2021;9:1323 PMCID:PMC8422151

[89] Zhou M,Zhao J.Extracellular vesicles derived from mesenchymal stem cells suppress breast cancer progression by inhibiting angiogenesis.Mol Med Rep2024;30:192

[90] Li T,Wang J.Adipose-derived mesenchymal stem cells and extracellular vesicles confer antitumor activity in preclinical treatment of breast cancer.Pharmacol Res2020;157:104843

[91] Nicodemou A,Čeháková M.Emerging roles of mesenchymal stem/stromal-cell-derived extracellular vesicles in cancer therapy.Pharmaceutics2023;15:1453 PMCID:PMC10221697

[92] Christodoulou I,Papaevangeliou D.Comparative evaluation of human mesenchymal stem cells of fetal (Wharton’s jelly) and adult (adipose tissue) origin during prolonged in vitro expansion: considerations for cytotherapy.Stem Cells Int2013;2013:246134 PMCID:PMC3603673

[93] Wang J,Huang R.Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes via endorsement of macrophage polarization.Stem Cell Res Ther2020;11:424 PMCID:PMC7522905

[94] Li J,Li T.Exosomes derived from mesenchymal stem cells attenuate the progression of atherosclerosis in ApoE^-/- mice via miR-let7 mediated infiltration and polarization of M2 macrophage.Biochem Biophys Res Commun2019;510:565-72

[95] Liu X,Lu L.Immunomodulatory potential of mesenchymal stem cell-derived extracellular vesicles: targeting immune cells.Front Immunol2023;14:1094685 PMCID:PMC9968735

[96] Franco da Cunha F,Candido de Almeida D.Extracellular vesicles isolated from mesenchymal stromal cells modulate CD4⁺ T lymphocytes toward a regulatory profile.Cells2020;9:1059 PMCID:PMC7226573

[97] Zhou W,Chen X.Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment.Biomaterials2021;268:120546

[98] Li D,Li G.Exosomes derived from mesenchymal stem cells curbs the progression of clear cell renal cell carcinoma through T-cell immune response.Cytotechnology2021;73:593-604 PMCID:PMC8319245

[99] Fan Y,Vernochet A,Oberlin E.Human fetal liver mesenchymal stem cell-derived exosomes impair natural killer cell function.Stem Cells Dev2019;28:44-55

[100] Zhang B,Lai RC,Choo AB.Mesenchymal stem cells secrete immunologically active exosomes.Stem Cells Dev2014;23:1233-44

[101] Hu W,Yu H,Zhao Y.Released exosomes contribute to the immune modulation of cord blood-derived stem cells.Front Immunol2020;11:165 PMCID:PMC7052489

[102] Wong RS,Lim JS.Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies.Cancer Drug Resist2023;6:768-87 PMCID:PMC10804393

[103] Liu H,Rasteh AM,Weng J.Identification of the novel exhausted T cell CD8 + markers in breast cancer.Sci Rep2024;14:19142 PMCID:PMC11333736

[104] Sil S,Liao K.Strategies for the use of extracellular vesicles for the delivery of therapeutics. 2020;15:422-42. PMCID:PMC7044028

[105] Agrahari V,Burnouf PA,Burnouf T.Extracellular microvesicles as new industrial therapeutic frontiers.Trends Biotechnol2019;37:707-29

[106] Ohno S,Kuroda M.Focus on extracellular vesicles: development of extracellular vesicle-based therapeutic systems.Int J Mol Sci2016;17:172 PMCID:PMC4783906

[107] György B,Breakefield XO.Therapeutic applications of extracellular vesicles: clinical promise and open questions.Annu Rev Pharmacol Toxicol2015;55:439-64 PMCID:PMC4445965

[108] Vader P,Pasterkamp G.Extracellular vesicles for drug delivery.Adv Drug Deliv Rev2016;106:148-56

[109] Kaur S,Elkahloun AG,Abu-Asab MS.CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells.Matrix Biol2014;37:49-59 PMCID:PMC6176487

[110] Chao MP,Majeti R.The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.Curr Opin Immunol2012;24:225-32 PMCID:PMC3319521

[111] Kamerkar S,Sugimoto H.Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.Nature2017;546:498-503 PMCID:PMC5538883

[112] Cooper JM,Nordin JZ.Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.Mov Disord2014;29:1476-85 PMCID:PMC4204174

[113] Alvarez-Erviti L,Yin H,Lakhal S.Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.Nat Biotechnol2011;29:341-5

[114] Kimiz-Gebologlu I.Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake.J Control Release2022;347:533-43

[115] Kang M,Blenkiron C.Biodistribution of extracellular vesicles following administration into animals: a systematic review.J Extracell Vesicles2021;10:e12085 PMCID:PMC8224174

[116] Li R,Liu H,Lin J.Abstract 2162: comparing volatile and intravenous anesthetics in a mouse model of breast cancer metastasis.Cancer Res2018;78:2162-2162

[117] Yang SS,Dou H.Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment.Exp Cell Res2020;391:111983

[118] Kia V,Paryan M,Mohammadi-Yeganeh S.Exosomal miRNAs from highly metastatic cells can induce metastasis in non-metastatic cells.Life Sci2019;220:162-8

[119] Wu H,Zhong H.Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing.Oncol Rep2020;43:240-50 PMCID:PMC6908931

[120] Eichelser C,Müller V.Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.Oncotarget2014;5:9650-63 PMCID:PMC4259427

[121] Stevic I,Weber K.Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.BMC Med2018;16:179 PMCID:PMC6178264

[122] Yu DD,Zhang XH.Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222.Tumour Biol2016;37:3227-35

[123] Wei Y,Yu S.Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.Breast Cancer Res Treat2014;147:423-31

[124] Donnarumma E,Nappa M.Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer.Oncotarget2017;8:19592-608 PMCID:PMC5386708

[125] Das K,Singh A.Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition.J Biol Chem2019;294:13681-96 PMCID:PMC6746455

[126] Mizenko RR,Bozkurt BT.A critical systematic review of extracellular vesicle clinical trials.J Extracell Vesicles2024;13:e12510 PMCID:PMC11428870

[127] Shojaei S,Ghanbarian H,Salehi M.Delivery of miR-381-3p mimic by mesenchymal stem cell-derived exosomes inhibits triple negative breast cancer aggressiveness; an in vitro study.Stem Cell Rev Rep2021;17:1027-38

[128] Shojaei S,Paryan M,Sharifi K.Mesenchymal stem cell-derived exosomes enriched with miR-218 reduce the epithelial-mesenchymal transition and angiogenesis in triple-negative breast cancer cells.Eur J Med Res2023;28:516 PMCID:PMC10647065

[129] Vakhshiteh F,Ostad SN,Dinarvand R.Exosomes derived from miR-34a-overexpressing mesenchymal stem cells inhibit in vitro tumor growth: a new approach for drug delivery.Life Sci2021;266:118871

[130] Zhou Y,Takeshita F,Xiao Z.Delivery of miR-424-5p via extracellular vesicles promotes the apoptosis of MDA-MB-231 TNBC cells in the tumor microenvironment.Int J Mol Sci2021;22:844 PMCID:PMC7831022

[131] Khazaei-Poul Y,Koochaki A,Mohammadi-Yeganeh S.Evaluating the influence of human umbilical cord mesenchymal stem cells-derived exosomes loaded with miR-3182 on metastatic performance of triple negative breast cancer cells.Life Sci2021;286:120015

[132] Sheykhhasan M,Sheikholeslami A,Amini E.Exosomes of mesenchymal stem cells as a proper vehicle for transfecting miR-145 into the breast cancer cell line and its effect on metastasis.Biomed Res Int2021;2021:5516078 PMCID:PMC8263260

[133] Kordelas L,Ludwig AK.MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease.Leukemia2014;28:970-3

[134] Tang M,Li B.Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis.FASEB J2021;35:e21557 PMCID:PMC10851328

[135] Zhang Y,Zhang X.Recent advances in exosome-mediated nucleic acid delivery for cancer therapy.J Nanobiotechnology2022;20:279 PMCID:PMC9194774